Nektar Therapeutics Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Nektar Therapeutics (NKTR) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $18.28 million as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-13
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $18.28M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $19.62M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $19.45M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $22.11M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $18.28M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $19.62M 10-K · filed 2026-03-13 | |
| 2023-12-31 | $19.45M 10-K · filed 2025-03-14 | |
| 2022-12-31 | $22.11M 10-K · filed 2024-03-05 | |
| 2021-12-31 | $33.41M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $32.52M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $30.88M 10-K · filed 2021-02-26 | |
| 2018-12-31 | $21.52M 10-K · filed 2020-02-28 | |
| 2017-12-31 | $14.55M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $26.36M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $22.83M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $21.95M 10-K · filed 2016-02-29 | |
| 2013-12-31 | $25.96M 10-K · filed 2015-02-26 | |
| 2012-12-31 | $23.75M 10-K · filed 2014-02-27 | |
| 2011-12-31 | $19.27M 10-K · filed 2013-03-01 | $32.27M 10-K · filed 2012-02-29 |
| 2010-12-31 | $28.16M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |